Similarly, medical studies report that new GLP-1 prescriptions have become predominantly for obesity rather than diabetes: e.g., in 20192023 only ~57% of new GLP-1 patients had T2D (down from ~65% a decade earlier) ( [27] ) ( [28] )
What do I pay
Injecting early only increases the medication concentration slightly and does not accelerate fat loss, but it may increase nausea
Additionally, NAC significantly lowered both total cholesterol and LDL levels, while metformin only reduced total cholesterol (145)
Continuous glucose monitoring (CGM) systems, when available, provide comprehensive data about glucose trends and variability
Monitoring prescribing trends and shortages: Truvetas daily-updated data allows for the monitoring of GLP-1 prescribing trends, helping researchers identify shifts in practice, as well as potential shortages of medications